sample of publications

• articles 

  • Comparison of 8 weeks standard treatment (rifampicin plus clarithromycin) vs. 4 weeks standard plus amoxicillin/clavulanate treatment [RC8 vs. RCA4] to shorten Buruli ulcer disease therapy (the BLMs4BU trial): study protocol for a randomized controlled multi-centre trial in Benin.  Trials (Trials).  23:1-17. 2022
  • Hit Compounds and Associated Targets in Intracellular Mycobacterium tuberculosis.  Molecules.  27:1-16. 2022
  • Two-way regulation of protein expression for identification and validation of on-target inhibitors of Mycobacterium tuberculosis.  FASEB JOURNAL.  36. 2022
  • The small-molecule SMARt751 reverses Mycobacterium tuberculosis resistance to ethionamide in acute and chronic mouse models of tuberculosis.  Science Translational Medicine.  14. 2022
  • Two-Way Regulation of MmpL3 Expression Identifies and Validates Inhibitors of MmpL3 Function in Mycobacterium tuberculosis.  ACS Infectious Diseases.  7:141-152. 2021
  • First-Time-in-Human Study and Prediction of Early Bactericidal Activity for GSK3036656, a Potent Leucyl-tRNA Synthetase Inhibitor for Tuberculosis Treatment.  ANTIMICROBIAL AGENTS AND CHEMOTHERAPY.  63. 2019
  • Dual Pharmacophore Pyrithione-Containing Cephalosporins Kill Both Replicating and Nonreplicating Mycobacterium tuberculosis.  ACS Infectious Diseases.  5:1433-1445. 2019
  • Inhibiting the stringent response blocks Mycobacterium tuberculosis entry into quiescence and reduces persistence.  Science Advances.  5. 2019
  • Triple oral beta-lactam containing therapy for Buruli ulcer treatment shortening.  PLoS Neglected Tropical Diseases.  2019
  • Novel insight into the reaction of nitro, nitroso and hydroxylamino benzothiazinones and of benzoxacinones with Mycobacterium tuberculosis DprE1.  Scientific Reports.  2018
  • Identification and characterization of aspartyl-tRNA synthetase inhibitors against Mycobacterium tuberculosis by an integrated whole-cell target-based approach.  Scientific Reports.  2018
  • Functional screening of selective mitochondrial inhibitors of Plasmodium.  International Journal for Parasitology-Drugs and Drug Resistance.  8:295-303. 2018
  • Screening of a Novel Fragment Library with Functional Complexity against Mycobacterium tuberculosis InhA.  ChemMedChem.  13:672-677. 2018
  • Prioritizing multiple therapeutic targets in parallel using automated DNA-encoded library screening.  Nature Communications.  2017
  • A new 'golden age" for the antitubercular target InhA.  DRUG DISCOVERY TODAY.  22:492-502. 2017
  • Repurposing clinically approved cephalosporins for tuberculosis therapy.  Scientific Reports.  6. 2016
  • Discovery of novel oral protein synthesis inhibitors of mycobacterium tuberculosis that target leucyl-tRNA synthetase.  ANTIMICROBIAL AGENTS AND CHEMOTHERAPY.  60:6271-6280. 2016
  • Identification of KasA as the cellular target of an anti-tubercular scaffold.  Nature Communications.  7. 2016
  • N-methylation of a bactericidal compound as a resistance mechanism in Mycobacterium tuberculosis.  PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA.  113. 2016
  • Antitubercular drugs for an old target: GSK693 as a promising InhA direct inhibitor.  EBioMedicine.  8:291-301. 2016
  • New molecular settings to support in vivo anti-malarial assays.  Malaria Journal (Malaria Journal).  15. 2016
  • N-Benzyl-4-((heteroaryl)methyl)benzamides: A New Class of Direct NADH-Dependent 2-trans Enoyl-Acyl Carrier Protein Reductase (InhA) Inhibitors with Antitubercular Activity.  ChemMedChem.  11:687-701. 2016
  • New direct inhibitors of InhA with antimycobacterial activity based on a tetrahydropyran scaffold.  EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY.  112:252-257. 2016
  • Release of 50 new, drug-like compounds and their computational target predictions for open source anti-tubercular drug discovery.  PLoS One.  10:1-18. 2015
  • Development of an intracellular screen for new compounds able to inhibit Mycobacterium tuberculosis growth in human macrophages.  ANTIMICROBIAL AGENTS AND CHEMOTHERAPY.  60:640-645. 2015
  • Mycobacterium tuberculosis gyrase inhibitors as a new class of antitubercular drugs.  ANTIMICROBIAL AGENTS AND CHEMOTHERAPY.  59. 2015
  • Encoded library technology as a source of hits for the discovery and lead optimization of a potent and selective class of bactericidal direct inhibitors of mycobacterium tuberculosis InhA.  JOURNAL OF MEDICINAL CHEMISTRY.  57:1276-1288. 2014
  • Tetrahydropyrazolo[1,5-a]Pyrimidine-3-Carboxamide and N-Benzyl-6¿,7¿-Dihydrospiro[Piperidine-4,4¿-Thieno[3,2-c]Pyran] Analogues with Bactericidal Efficacy against Mycobacterium tuberculosis Targeting MmpL3.  PLoS One.  2013
  • Fueling Open-Source Drug Discovery: 177 Small-Molecule Leads against Tuberculosis.  ChemMedChem.  8:313-321. 2013
  • Streptomycin-starved Mycobacterium tuberculosis 18b, a drug discovery tool for latent tuberculosis.  ANTIMICROBIAL AGENTS AND CHEMOTHERAPY.  56. 2012
  • A new molecular approach for cidal vs static antimalarial determination by quantifying mRNA levels.  MOLECULAR AND BIOCHEMICAL PARASITOLOGY.  181:171-177. 2011
  • 4-Substituted Thioquinolines and Thiazoloquinolines: Potent, Selective, and Tween-80 invitro Dependent Families of Antitubercular Agents with Moderate invivo Activity.  ChemMedChem.  6:2252-2263. 2011
  • A murine model of falciparum-malaria by in vivo selection of competent strains in non-myelodepleted mice engrafted with human erythrocytes.  PLoS One.  3. 2008

• book chapters 

  • Antimicrobial Susceptibility Testing for Mycobacterium sps in High-Throughput Format. In: Methods in Molecular Biology.  SPRINGER SCIENCE BUSINESS MEDIA B.V.. 637-648. 2021
  • Antimicrobial susceptibility testing for Mycobacterium sp. In: Methods in Molecular Biology.  SPRINGER NATURE LIMITED. 257-268. 2015